Cargando…

Efficacy of combined treatment with pasireotide, pegvisomant and cabergoline in an acromegalic patient resistant to other treatments: a case report

BACKGROUND: The approach to acromegalic patients with persistent acromegaly after surgery and inadequate response to first-generation somatostatin receptor ligands (SRLs) should be strictly tailored. Current options include new pituitary surgery and/or radiosurgery, or alternative medical treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ciresi, A., Radellini, S., Guarnotta, V., Giordano, C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5781307/ https://www.ncbi.nlm.nih.gov/pubmed/29361932 http://dx.doi.org/10.1186/s12902-018-0231-9

Ejemplares similares

Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant
por: Chiloiro, Sabrina, et al.
Publicado: (2021)

The metabolic outcomes of growth hormone treatment in children are gender specific
por: Ciresi, Alessandro, et al.
Publicado: (2018)

Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing’s disease
por: Feelders, Richard A., et al.
Publicado: (2023)

Pasireotide in an insulin-requiring diabetic acromegalic patient without worsening of hyperglycemia
por: Gordon, Murray B, et al.
Publicado: (2017)

More Favorable Metabolic Impact of Three-Times-Weekly versus Daily Growth Hormone Treatment in Naïve GH-Deficient Children
por: Ciresi, Alessandro, et al.
Publicado: (2017)

Pegvisomant-Induced Cholestatic Hepatitis in an Acromegalic Patient with UGT1A1 (⁎) 28 Mutation
por: Mallea-Gil, Maria Susana, et al.
Publicado: (2016)

SUN-LB075 Effects of Pegvisomant and Pasireotide LAR on Incidence of Vertebral Fractures in Patients with Acromegaly Resistant to Treatment with First-Line Somatostatin Analogs
por: Chiloiro, Sabrina, et al.
Publicado: (2019)

Combined treatment of somatostatin analogues with pegvisomant in acromegaly
por: Franck, S. E., et al.
Publicado: (2015)

MON-311 Glucose Metabolism in Acromegaly Patients Resistant to First Generation Somatostatin Receptor Ligands Treated with Pegvisomant And/Or Pasireotide Lar
por: Chiloiro, Sabrina, et al.
Publicado: (2020)

Nanomedicines in the treatment of acromegaly: focus on pegvisomant
por: Roelfsema, Ferdinand, et al.
Publicado: (2006)

Hepatic Steatosis Index in Acromegaly: Correlation with Insulin Resistance Regardless of the Disease Control
por: Ciresi, Alessandro, et al.
Publicado: (2018)

Brazilian multicenter study on pegvisomant treatment in acromegaly
por: Boguszewski, Cesar L., et al.
Publicado: (2019)

Acromegale
por: Robertson, W.
Publicado: (1893)

Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients
por: Neggers, Sebastian J. C. M. M., et al.
Publicado: (2011)

The medical treatment with pasireotide in Cushing’s disease: an Italian multicentre experience based on “real-world evidence”
por: Pivonello, Rosario, et al.
Publicado: (2019)

Incretin Response to Mixed Meal Challenge in Active Cushing’s Disease and after Pasireotide Therapy
por: Barbot, Mattia, et al.
Publicado: (2022)

Pegvisomant in acromegaly: an update
por: Giustina, A., et al.
Publicado: (2017)

Pasireotide in the Personalized Treatment of Acromegaly
por: Puig-Domingo, Manel, et al.
Publicado: (2021)

Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study
por: Kuhn, Emmanuelle, et al.
Publicado: (2020)

One Year of Dapaglifozin Add-On Therapy Ameliorates Surrogate Indexes of Insulin Resistance and Adiposity in Patients with Type 2 Diabetes Mellitus
por: Radellini, Stefano, et al.
Publicado: (2021)

Correction to: One Year of Dapaglifozin Add-On Therapy Ameliorates Surrogate Indexes of Insulin Resistance and Adiposity in Patients with Type 2 Diabetes Mellitus
por: Radellini, Stefano, et al.
Publicado: (2021)

Safety and Efficacy of Pegvisomant in Pediatric Growth Hormone Excess
por: Tatsi, Christina, et al.
Publicado: (2021)

Increasing frequency of combination medical therapy in the treatment of acromegaly with the GH receptor antagonist pegvisomant
por: Strasburger, Christian J, et al.
Publicado: (2018)

Correction to: Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study
por: Kuhn, Emmanuelle, et al.
Publicado: (2020)

Liraglutide Improves Cardiovascular Risk as an Add-on to Metformin and Not to Insulin Secretagogues in Type 2 Diabetic Patients: A Real-life 48-Month Retrospective Study
por: Ciresi, Alessandro, et al.
Publicado: (2017)

Author Correction: Liraglutide Improves Cardiovascular Risk as an Add-on to Metformin and Not to Insulin Secretagogues in Type 2 Diabetic Patients: A Real-life 48-Month Retrospective Study
por: Ciresi, Alessandro, et al.
Publicado: (2018)

Case report: Treatment of psychiatric symptoms for an acromegalic patient with pituitary adenoma
por: Shi, Zhongyong, et al.
Publicado: (2022)

Sensorineural hearing loss in acromegalic patients under treatment
por: Carvalho, Marcelo Alexandre, et al.
Publicado: (2015)

Abstract 94: Efficacy of cabergoline treatment in men with giant prolactinomas
Publicado: (2022)

Combined therapy of somatostatin analogues with pegvisomant for the treatment of acromegaly: a meta-analysis of prospective studies
por: Ma, Lingyun, et al.
Publicado: (2020)

Effects of Pituitary Surgery and High-Dose Cabergoline Therapy on Metabolic Profile in Patients With Prolactinoma Resistant to Conventional Cabergoline Treatment
por: Pirchio, Rosa, et al.
Publicado: (2021)

Cabergoline Treatment in Invasive Giant Prolactinoma
por: Alsubaie, Sadeem, et al.
Publicado: (2014)

Gender-specific soluble α-klotho levels as marker of GH deficiency in children: a case–control study
por: Guarnotta, V., et al.
Publicado: (2022)

Pegvisomant for acromegaly: does it always works?
por: Neggers, Sebastian J., et al.
Publicado: (2019)

Efficacy of cabergoline add-on therapy in patients with acromegaly resistance to somatostatin analogs treatment and the review of literature
por: Kizilgul, Muhammed, et al.
Publicado: (2022)

Pasireotide: a novel treatment for patients with acromegaly
por: Cuevas-Ramos, Daniel, et al.
Publicado: (2016)

Efficacy and Safety of Cabergoline as First Line Treatment for Invasive Giant Prolactinoma
por: Cho, Eun-Hee, et al.
Publicado: (2009)

Report upon the Examination of the Body of an Acromegalic Subject
por: Geddes, A. Campbell
Publicado: (1909)

Metabolic Profile in a Cohort of Young Sicilian Patients with Klinefelter's Syndrome: The Role of Irisin
por: Radellini, Stefano, et al.
Publicado: (2022)

Pseudoacromegaly with acromegalic features in radiography
por: Yamamoto, Koichiro, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_l9e6rgof204g0spu7pofmnsebn